EUCTR2008-002661-30-IT进行中（未招募）不适用
se of Maraviroc (MVC) in immunogical non-responder HIV-1-infected patients. - ND
AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)0 个研究点开始时间: 2008年6月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •HIV+ patients (aged 18 yrs or older) with a CD4 count ≤ 200 cells/uL and/or a recovery of CD4 cells < 25% compared to the HAART initiation and/or a stable CD4 slope without any improvement, with an absolute value around 200 cells/uL and with a complete and stable virologic suppression after 12 months of HAART.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Intolerance to Maraviroc (MVC); treatment with immunomodulant agents; chronic inflammatory diseases; biochemical toxicity of grade 3-4.
研究者
相似试验
进行中（未招募）
不适用
(Maraviroc ENHancement of Immunological Response): A pilot study of maraviroc as an add-on in patients with reduced CD4 cell count despite full viral suppression - MENHIREUCTR2010-019518-25-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)
进行中（未招募）
不适用
Maraviroc Immune Recovery Study (MIRS):A multicentre, randomized, placebo-controlled, exploratory mechanistic study into the role of Maraviroc on immune recovery - MIRSEUCTR2008-003635-20-NLniversitair Medisch Centrum Utrecht
已完成
4 期
Maraviroc Immune Recovery Study (MIRS): A multicentre, randomized, placebo-controlled, exploratory mechanistic study into the role of Maraviroc on immune recoveryHIVhuman immunodeficiency virus10047438NL-OMON35447niversitair Medisch Centrum Utrecht130
Unknown
4 期
Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3HIV-1 InfectionNCT01235013Hospital Clinic of Barcelona60
尚未招募
不适用
Maraviroc Immune Recovery Study.HIVNL-OMON24984MC Utrecht130